Skip to main content
MMEDMiniMed Group, Inc.Sell5.9·$15.99-2.11%
MMED · Concentration risk · 10-K extracted

MiniMed Group (MMED) concentration risks

Updated

The most significant concentration MiniMed Group discloses is Convatec, Forj Medical and Steris sole-source suppliers, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Source: MiniMed Group’s SEC Form 10-K filed view the filing on SEC EDGAR ↗

At a glance

Disclosed-size breakdown · 1 disclosed concentration

HIGH1
MEDIUM0
LOW0
Disclosed concentrations

Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).

HIGHOutside partySupplier

Convatec, Forj Medical and Steris sole-source suppliers

10-K Item 1A: 'Our sole suppliers include Convatec Group plc for the infusion sets used in our insulin pumps, Forj Medical (f/k/a Intricon Corporation) for transmitters, and Steris plc and Steri-Tech Inc. for sterilization services.'
SEC 10-K · filed Jun 2026
TrendMatrix Research · concentration synthesis

What these concentrations mean together

updated 2026-07-06

MiniMed Group's principal disclosed concentration sits on the supply side: the company relies on sole-source suppliers for critical components of its insulin pump system — Convatec Group for infusion sets, Forj Medical (formerly Intricon) for transmitters, and Steris plc and Steri-Tech for sterilization services. This is a high-size dependency exposure, and notably it is spread across three distinct suppliers covering three different functions rather than a single point of failure, though each individual relationship is itself sole-sourced with no disclosed alternative. Unlike a customer or geographic concentration, this risk is idiosyncratic to each supplier relationship — a manufacturing disruption, quality issue, or contract dispute at any one of these three companies could interrupt MiniMed's ability to manufacture or ship its insulin pumps, independent of end-market demand or macro conditions. Because no other concentration claims are disclosed in the reviewed sources, this supply-chain dependency is the dominant risk factor for the name: the investment case depends not only on demand for the insulin pump product but on the continued reliability of these three sole-source relationships.

For the engine’s reasoning on MMED’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Industry peers · Medical Instruments & Supplies

Peer concentration profile

SymbolNameHIGHMEDIUMLOWTotal
ANGOAngioDynamics, Inc.2103
ATRCAtriCure, Inc.1113
ATRAptarGroup, Inc.1102
ALGNAlign Technology, Inc.1001
AVRAnteris Technologies Global Cor1001
MMEDMiniMed Group, Inc.1001

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.

Concentration disclosures are extracted verbatim from SEC 10-K filings; the disclosed-size classification and the synthesis above are engine-derived. Size reflects how large each exposure is against fixed share thresholds (HIGH >50%, MEDIUM 25–50%, LOW <25% or an explicit diversification statement), not a judgment of how dangerous it is, and is not a buy/sell rating, a price target, or a view on the stock. Not a complete list of risk factors — see the full filing.

Home Stocks MMED Concentration risk